Product name
Immunotherapy with Tumour-Associated Antigens Derived from PAX2 and PAX8Summary
Immunogenic T-cell epitopes found promising immunotherapeutcs against renal, colorectal, breast and ovarian cancer.Organization name
ipal GmbHProfile
The PAX (paired axial) genes belong to the homeobox gene family of transcription factors. Both PAX2 and PAX8 genes play a role in the developing kidney and in the regulation of expression of the Wilms Tumor Gene (WT1).
Today it is established that the Wilms Tumor Gene (WT1) is expressed in leukaemic blasts and in solid tumors, e.g. in colorectal, breast and lung cancers. WT1 plays a key pathogenic role as down-regulation of w1 gene leads to growth arrest, differentiation and apoptosis. Also PAX2 and PAX8 are expressed in various types of cancer.
The inventor and colleagues could recently show that expression of PAX2 and PAX8 is a cause of up-regulation of WT1 in human acute myeloid leukaemia (AML), breast and colorectal carcinomas. Therefore, in addition to WT1 as target for immunotherapy itself, it is of great interest to exploit the WT1 expression regulators PAX2 and PAX8 as cancer vaccination antigen.
Benefits
- Tumor vaccination with a promising cancer specific epitope
- Less side effects expected than with the cytotoxic approach
Application
Vaccination therapy of
- renal cancer
- colorectal cancer
- breast cancer
- ovarian cancer
Results from the screenings are available online at www.ipal.de/en/technology_offers/life_sciences/.
The technology is offered by IPAL.
Contact
IPAL GmbH
Dr. Petra Düx
petra.duex(at)ipal.de
About IPAL
The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitaetsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialprüfung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.
print this page
